Your browser doesn't support javascript.
loading
Quadrivalent influenza nanoparticle vaccines induce broad protection.
Boyoglu-Barnum, Seyhan; Ellis, Daniel; Gillespie, Rebecca A; Hutchinson, Geoffrey B; Park, Young-Jun; Moin, Syed M; Acton, Oliver J; Ravichandran, Rashmi; Murphy, Mike; Pettie, Deleah; Matheson, Nick; Carter, Lauren; Creanga, Adrian; Watson, Michael J; Kephart, Sally; Ataca, Sila; Vaile, John R; Ueda, George; Crank, Michelle C; Stewart, Lance; Lee, Kelly K; Guttman, Miklos; Baker, David; Mascola, John R; Veesler, David; Graham, Barney S; King, Neil P; Kanekiyo, Masaru.
Afiliação
  • Boyoglu-Barnum S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ellis D; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Gillespie RA; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Hutchinson GB; Graduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA, USA.
  • Park YJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Moin SM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Acton OJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Ravichandran R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Murphy M; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Pettie D; Macromolecular Structure Laboratory, The Francis Crick Institute, London, UK.
  • Matheson N; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Carter L; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Creanga A; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Watson MJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Kephart S; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Ataca S; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Vaile JR; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Ueda G; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Crank MC; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Stewart L; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Lee KK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Guttman M; Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.
  • Baker D; Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Veesler D; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Graham BS; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • King NP; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Kanekiyo M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nature ; 592(7855): 623-628, 2021 04.
Article em En | MEDLINE | ID: mdl-33762730
ABSTRACT
Influenza vaccines that confer broad and durable protection against diverse viral strains would have a major effect on global health, as they would lessen the need for annual vaccine reformulation and immunization1. Here we show that computationally designed, two-component nanoparticle immunogens2 induce potently neutralizing and broadly protective antibody responses against a wide variety of influenza viruses. The nanoparticle immunogens contain 20 haemagglutinin glycoprotein trimers in an ordered array, and their assembly in vitro enables the precisely controlled co-display of multiple distinct haemagglutinin proteins in defined ratios. Nanoparticle immunogens that co-display the four haemagglutinins of licensed quadrivalent influenza vaccines elicited antibody responses in several animal models against vaccine-matched strains that were equivalent to or better than commercial quadrivalent influenza vaccines, and simultaneously induced broadly protective antibody responses to heterologous viruses by targeting the subdominant yet conserved haemagglutinin stem. The combination of potent receptor-blocking and cross-reactive stem-directed antibodies induced by the nanoparticle immunogens makes them attractive candidates for a supraseasonal influenza vaccine candidate with the potential to replace conventional seasonal vaccines3.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Influenza A / Vacinas contra Influenza / Nanomedicina / Influenza Humana / Nanopartículas / Anticorpos Amplamente Neutralizantes Limite: Animals / Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Influenza A / Vacinas contra Influenza / Nanomedicina / Influenza Humana / Nanopartículas / Anticorpos Amplamente Neutralizantes Limite: Animals / Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos